Lilly: Taltz + Zepbound superior to Taltz alone in psoriatic arthritis with obesity

Key highlights
  • Phase 3b TOGETHER-PsA randomized 52-week trial (NCT06588296) with 271 adults compared Taltz (ixekizumab) plus Zepbound (tirzepatide) versus Taltz alone, with primary endpoint at 36 weeks.
  • Primary endpoint at 36 weeks: ACR50 plus ≥10% weight reduction achieved in 31.7% with combination versus 0.8% with Taltz alone.
  • Combination also showed higher ACR50 (33.5% vs 20.4%), ≥10% weight loss (84.5% vs 4.5%) and improvements in MDA, fatigue, function, hsCRP and cardiometabolic markers.
  • Adverse events with the combination were generally mild-to-moderate; most common (≥5%) were nausea, diarrhea, constipation and injection-site reactions.

Study design

TOGETHER-PsA is a 52-week, randomized, multicenter, assessor-blinded, open-label Phase 3b trial (NCT06588296) in 271 adults with active psoriatic arthritis and obesity/overweight plus ≥1 weight-related comorbidity; participants were randomized 1:1 to subcutaneous ixekizumab (Taltz) alone or concomitant ixekizumab and tirzepatide (Zepbound); primary endpoint was proportion achieving ACR50 and ≥10% weight reduction at Week 36.

Efficacy

At Week 36 the combination met the primary endpoint: 31.7% vs 0.8% (combination vs Taltz). Combination also showed higher ACR50 (33.5% vs 20.4%), ACR20+≥5% weight loss (69.7% vs 10.3%), ≥10% weight loss (84.5% vs 4.5%) and increased Minimal Disease Activity (26.3% vs 15.3%). Improvements were observed in hsCRP (−1.79 vs −0.44 mg/L), HAQ-DI (−0.5 vs −0.3), FACIT-Fatigue (8.6 vs 4.8) and SF-36 Mental Component Score (3.1 vs 0.4). An increased ACR50 was seen as early as Week 4, prior to clinically meaningful weight loss.

Safety

Adverse events with concomitant therapy were generally mild to moderate and consistent with known profiles; most common (≥5%) in the combination arm were nausea, diarrhea, constipation and injection-site reactions; Taltz monotherapy most commonly reported injection-site reactions and upper respiratory tract infections.

Dissemination

Results were presented as a late-breaking presentation at the 2026 AAD Annual Meeting and published in Arthritis & Rheumatology.

Source: Lilly

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

9 October 2026
Eli Lilly: Taltz plus Zepbound show broader immunometabolic biomarker changes in TOGETHER‑PsO

Combination therapy produced broader psoriasis-related and metabolic biomarker changes vs Taltz alone as early as Week 12, with greater reductions in inflammatory and neutrophil markers.

5 October 2026
Lilly presents 21 dermatology posters at Fall Clinical Dermatology 2026

EBGLYSS shows durable control, less maintenance dosing and reduced topical use; TOGETHER‑PsO biomarker data assess Taltz+Zepbound vs Taltz; Olumiant pediatric alopecia areata results also included.

31 August 2026
Eli Lilly: Taltz plus Zepbound sustain improved psoriatic and metabolic outcomes at 52 weeks

Combination maintained or deepened psoriasis and psoriatic arthritis responses and reduced systemic inflammation while improving metabolic measures including BMI and HbA1c at one year versus Taltz alone.

1 October 2026
Lilly: Foundayo linked to reduced 10‑year predicted type 2 diabetes and cardiovascular risk

Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.

30 September 2026
Lilly's EloraTZP (eloralintide + tirzepatide) outperforms tirzepatide 15 mg in Phase 2b obesity and T2D trial

Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.